scholarly journals Surfactant protein D, a clinical biomarker for chronic obstructive pulmonary disease with excellent discriminant values

2016 ◽  
Vol 11 (3) ◽  
pp. 723-730 ◽  
Author(s):  
ZEINA AKIKI ◽  
DALIA FAKIH ◽  
RANIA JOUNBLAT ◽  
SOULAIMA CHAMAT ◽  
MIRNA WAKED ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Surfactant Protein ◽  
Surfactant Protein D ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Clinical Biomarker

Surfactant protein D in chronic obstructive pulmonary disease and type 2 diabetes mellitus

2017 ◽  
Vol 30 (1) ◽  
pp. 297
Author(s):  
MaiA.H. Abou Elenin ◽  
NaglaaM Ghanayem ◽  
ElsayedS Abou Elnour ◽  
RababA El Wahsh ◽  
RaniaM.A. El-Shazlya
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Chronic Obstructive Pulmonary Disease ◽  
Type 2 Diabetes Mellitus ◽  
Pulmonary Disease ◽  
Surfactant Protein ◽  
Surfactant Protein D ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

scholarly journals Polymorphisms in Surfactant Protein–D Are Associated with Chronic Obstructive Pulmonary Disease

2011 ◽  
Vol 44 (3) ◽  
pp. 316-322 ◽  
Author(s):  
Marilyn G. Foreman ◽  
Xiangyang Kong ◽  
Dawn L. DeMeo ◽  
Sreekumar G. Pillai ◽  
Craig P. Hersh ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Surfactant Protein ◽  
Surfactant Protein D ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

scholarly journals Serum Surfactant Protein D: Biomarker of Chronic Obstructive Pulmonary Disease

2012 ◽  
Vol 32 (5) ◽  
pp. 281-287 ◽  
Author(s):  
Chun-Rong Ju ◽  
Wei Liu ◽  
Rong-Chang Chen
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Airflow Obstruction ◽  
Surfactant Protein ◽  
Specific Protein ◽  
Surfactant Protein D ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Bode Index ◽  
Severity Of The Disease

Background: Surfactant protein D (SP-D) is a lung-specific protein proposed to predict clinical outcomes in patients with chronic obstructive pulmonary disease (COPD). However, the changes in serum SP-D during acute exacerbation (AECOPD) episodes and the relationship of serum SP-D with the overall severity of the disease in stable COPD (SCOPD) remain unclear.Methods: Serum SP-D levels were analyzed in three groups, including AECOPD (n=40), SCOPD (n=71), and controls (n=60). In AECOPD group, serum SP-D levels were determined at 1, 5, 14, and 30 days post-exacerbation. In SCOPD group, BODE (body mass index, airflow obstruction, dyspnea, exercise capacity) index was evaluated for severity assessment.Results: Serum SP-D levels were sequentially elevated from the controls to the SCOPD, and then to the AECOPD (p< 0.001). During an AECOPD episode, the raised serum SP-D levels subsided at day 5 (p> 0.05), fell markedly at day 14 (p< 0.001), and continued to decline at day 30 (p< 0.001). Among patients with SCOPD, serum SP-D levels correlated positively with the BODE index (p< 0.01).Conclusions: The longitudinal changes in serum SP-D levels during an AECOPD episode suggest that SP-D may be a potential systemic biomarker for COPD exacerbation. The correlation of serum SP-D levels with the BODE index suggests that circulating SP-Ds can reflect the overall severity of SCOPD.

Sign in / Sign up

Export Citation Format

Share Document